Lipella Pharmaceuticals (LIPO) announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 for the treatment of Oral Lichen Planus will be presented at the 2025 joint international meeting of the American Academy of Oral Medicine (AAOM) and the European Association of Oral Medicine in Las Vegas. Treatment at the 0.50 mg dose demonstrated statistically significant improvements in multiple endpoints: Investigator Global Assessment: Improved from 3.42 at baseline to 1.71 at Week 4; REU Score: Reduced from 26.91 to 11.88 at Week 4; Oral Lichen Planus Symptom Severity Measure: Dropped from 14.92 to 4.88 at Week 4; Pain Numerical Rating Scale: Improved from 6.42 to 2.25 at Week 4.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Reports Statistically Significant Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus
- Lipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOM
- Lipella Pharmaceuticals announces results from second cohort of LP-310 trial
- Lipella Pharmaceuticals completes enrollment in LP-310 trial
- Lipella Pharmaceuticals files to sell 5.62M shares of common stock for holders